<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have identified three unbalanced translocations involving chromosomes 5 and 17, der(5)t(5;17), der(17)t(5;17), and dic(5;17), in the malignant cells from 17 patients with myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Six patients had a primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) de novo; ten patients had <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and one patient had <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Two of the six patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> de novo had extensive exposure to industrial solvents, and one patient had <z:e sem="disease" ids="C0265202" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Seckel syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The primary diagnoses for the ten patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> in two patients each, and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp>, <z:hpo ids='HP_0002890'>thyroid carcinoma</z:hpo>, and <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> in one patient each </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients had received both prior chemotherapy and radiotherapy, four others received prior chemotherapy only, and the remaining two patients only prior radiotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Fluorescence in situ hybridization of centromere-specific probes for chromosomes 5 and 17 revealed that a dicentric rearrangement was the most common (13/16 patients examined) </plain></SENT>
<SENT sid="6" pm="."><plain>The genetic consequences of these chromosomal rearrangements are partial <z:mp ids='MP_0004026'>monosomy</z:mp> for 5q and 17p </plain></SENT>
<SENT sid="7" pm="."><plain>Two of six patients examined had point mutations in TP53, suggesting that loss of function of TP53 in addition to loss of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene on 5q may be involved in the pathogenesis of the malignant disease in some of these patients </plain></SENT>
</text></document>